Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Jan 6;20(2):379–388. doi: 10.1158/1055-9965.EPI-10-0998

Table 2.

Distribution of selected characteristics by history of menopausal symptoms among controls

Characteristics Never had menopausal symptoms (n=51) Ever had menopausal symptoms, but not severe symptoms (n=214) Ever had severe symptoms (n=180)
n (%) n (%) n (%)
Age (years)
55–59 12 (23.5) 54 (25.2) 63 (35.0)
60–64 6 (11.8) 59 (27.6) 50 (27.8)
65–69 14 (27.4) 51 (23.8) 44 (24.4)
70–74 19 (37.3) 50 (23.4) 23 (12.8)
First-degree family history of breast cancer
No 37 (80.4) 173 (82.8) 152 (87.4)
Yes 9 (19.6) 36 (17.2) 22 (12.6)
BMI (kg/m2)
<23.4 13 (25.5) 55 (25.9) 44 (24.4)
23.4–26.4 14 (27.5) 62 (29.3) 37 (20.6)
26.5–31.0 17 (33.3) 50 (23.6) 44 (24.4)
≥31.1 7 (13.7) 45 (21.2) 55 (30.6)
Recency of alcohol consumption
Never users 21 (41.2) 69 (32.7) 77 (43.0)
Former users 8 (15.7) 33 (15.6) 26 (14.5)
Current users 22 (43.1) 109 (51.7) 76 (42.5)
 <1 drinks/day 6 (27.3) 23 (21.1) 14 (18.4)
 ≥1 drink/day 16 (72.7) 86 (78.9) 62 (81.6)
Type of menopause
Natural 22 (43.1) 136 (63.6) 98 (54.5)
Induced 16 (31.4) 26 (12.1) 33 (18.3)
Simple hysterectomy 13 (25.5) 52 (24.3) 49 (27.2)
Age at menopause (years)
<45 9 (26.5) 19 (12.3) 28 (22.0)
45–54 20 (58.8) 109 (70.8) 73 (57.5)
≥55 5 (14.7) 26 (16.9) 26 (20.5)
Recency of menopausal hormone therapy use
Never 15 (29.4) 48 (22.4) 24 (13.3)
Former 15 (29.4) 58 (27.1) 50 (27.8)
Current unopposed estrogen 16 (31.4) 58 (27.1) 67 (37.2)
Current estrogen+progestin 5 (9.8) 50 (23.4) 39 (21.7)
Duration of hormone therapy use(years)
Never 15 (29.4) 48 (22.4) 24 (13.3)
<1 4 (7.8) 20 (9.4) 12 (6.7)
1–4 9 (17.7) 31 (14.5) 32 (17.8)
5–9 3 (5.9) 46 (21.5) 38 (21.1)
10–14 2 (3.9) 26 (12.1) 25 (13.9)
≥15 18 (35.3) 43 (20.1) 49 (27.2)